TP与NP方案治疗晚期非小细胞肺癌对比观察  

Comparison of TP and NP Regimen in Patients with Advanced Non-small Cell Lung Cancer

作　　者：黄锡梅[1] 苏炳光[1] 吴春林[1] 

机构地区：[1]广东医学院附属高州医院(高州市人民医院)肿瘤化疗科,525200

出　　处：《实用全科医学》2007年第4期306-307,共2页Applied Journal Of General Practice

摘　　要：目的比较泰素-顺铂（TP）方案与诺维本-顺铂（NP）方案治疗晚期非小细胞肺癌的疗效和毒性。方法97例经病理或细胞学确诊的Ⅳ期非小细胞肺癌随机分2组。TP方案组49例，泰素135mg／m^2，静脉滴注，第1天；顺铂40mg／次，静脉滴注，第2—4天。NP方案组48例，诺维本25mg／m^2，静脉点滴，第1，8天；顺铂用法用量同TP组。每4周为1个周期。结果TP方案组有效率57．14％，患者中位生存期为9个月；NP方案组有效率60．42％，患者中位生存期为10个月，两组间疗效差异无统计学意义。两组的主要不良反应为白细胞减少、脱发、恶心呕吐。两组间白细胞减少及脱发发生率差异均无统计学意义（均P〉0．05），TP组的恶心呕吐及肌肉关节酸痛发生率较NP组高（均P〈0．05）。结论TP方案与NP方案治疗晚期非小细胞肺肺癌均有较好疗效，疗效相近，不良反应可耐受。Objective To comparison the efficacy and toxicity of TP and NP chemotherapeutic regimens for patients with advanced non-small cell lung cancer （ NSCLC ）. Methods Ninety-seven patients confirmed as Stage IV NSCLC with histology or cytology were randomly divided into two groups： 49 patients received paclitaxel-cisplatin （TP regimen） and 48 patients received navelbine-cisplatin （ NP regimen）. Paclitaxel 135 mg/m^2 by infusion on clay 1 and cisplatin 40 mg/m^2 by infusion on clay 2 ～4 in TP. Navelbine （NVB） 25 mg/m^2 by infusion on clay 1,8 in NP, and cisplatin was same to TP. The treatment was repeated every 4 week. Results The objective response rate was 57.14% in TP regimen, the Median survival time was 9 months. The objective response rate was 60.42% in NP regimen, the Median survival time was 10 months. There was no significant difference between the two regimens. The major side effects were leukopenia, alopecia and nausea/vomiting in the two groups. The was no signifi- cant different in leukopenia and alopecia between TP regimen and NP regimen （ 87.76% vs 93.75 % , P 〉 0.05, 85.71% vs 79. 17% ,P 〉0.05, respectively）. The incidences of nausea/vomiting and pain of joint and muscle occurred more frequently in TP group than those in NP group. Conclusions Both TP and NP regimens have similar good effect for advanced non-small cell lung cancer. Side effects were well tolerated.

关 键 词：肺肿瘤 泰素-顺铂 诺维本-顺铂 

分 类 号：R734.2[医药卫生—肿瘤] R979.1[医药卫生—临床医学]